"The two words ‘information’ and ‘communication’ are often used interchangeably, but they signify quite different things. Information is giving out; communication is getting through." -- Sydney J. Harris

MNCM Seeks Public Comment on New Cancer Care Measure

MN Community Measurement (MNCM) invites you to provide feedback on the measure specifications for the Symptom Control During Chemotherapy measure set.

These measures were developed by the MNCM-convened, multi-stakeholder Cancer Care Measure Development Workgroup and are planned for pilot testing in oncology practices. The public comment period will conclude on Tuesday, November 17th at 11:59 p.m. CST.


In 2015, MNCM received approval from the Measurement and Reporting Committee (MARC) and the Board of Directors to convene a workgroup to explore measure development for patients undergoing chemotherapy and/or radiation therapy treatment for cancer. The direction was to focus on patient reported outcome measures that indicate better symptom control. The workgroup, chaired by Nicole Hartung, M.D from Minnesota Oncology Hematology, PA., included representation from oncology, oncology nurse practitioners, primary care, health IT, data analytics, quality improvement, health plans, state agency, the American Cancer Society and the American Society of Clinical Oncology.

Leveraging MNCM’s experience with developing patient reported outcome measures, the workgroup developed the Symptom Control During Chemotherapy measure set. (See the workgroup roster.) Measure development work concluded in November 2015 and the measures are recommended for testing in oncology practices.

These measure development activities are not currently included in the Statewide Quality Reporting and Measurement System (SQRMS) and will rely on voluntary participation from oncology practices.

Public Comment

A critical element of developing and testing measures by MNCM is the opportunity for the public to review proposed specifications and recommend changes or clarifications. We are seeking public comment on the Direct Data Submission (DDS) specifications for the measure set, which can be accessed here: Draft MNCM Chemotherapy Symptom Control Measure Specifications. All comments will be reviewed for consideration. Feedback should be submitted to by Tuesday, November 17th at 11:59 p.m. CST.

If you have any questions, please contact MNCM Measure Developer Collette Pitzen at or 612-454-4515. We appreciate your time and thoughtful comments.